血浆纤溶酶原激活物抑制物-1、玻璃体连接蛋白与血管重构
出处
《临床医药实践》
2004年第6期403-406,共4页
Proceeding of Clinical Medicine
参考文献19
-
1Allison BA,Nilsson L,Karpe F et al.Effects of native,triglyceride-enriched,and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells[J].Arterioscler Thromb Vasc Biol,1999,19:1354～1360.
-
2Dichtl W,Stiko A,Eriksson P et al.Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells[J].Arterioscler Thromb Vasc Biol,1999,19:3025～3032.
-
3David A,Waltz LR Natkin RW et al.Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin[J].J Clin Invest,1997,100(1):58～67.
-
4Tomasini BR,Mosher DF.Conformational states of vitronectin:preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thtombin-antithrombin Ⅲ or treated with urea[J].Blood,1988,72(3):903～912.
-
5Sobel BE,Woodcock-Mitchell J,Schneider DJ et al.Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients.A potential factor predisposing to thrombosis and its persist
-
6Estelles A,Tormo G,Aznar J et al.Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise[J].THromb Res,1985,(40):373.
-
7Sawa H,Lundgren C,Sobel BE et al.Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury :A potential progenitor of restenosis[J].J Am Coll Cardiol,1994,24:1742-1748.
-
8Bourcier T,Libby P.HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells[J].Arterioscler Thromb Vasc Biol,2000,20:556-562.
-
9Thyberg J,Hedin U,Sjolund M.Regulatiion of differentiated properties and proliferation of arterial smooth muscle cells[J].Arteriosclerosis,1990,10:966-990.
-
10Podor TJ,Peterson CB,Lawrence DA et al.Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin[J].J Biol Chem,2000,275:19788-19794.
-
1杨伟,王立,万桂英.血浆PAI-1水平与2型糖尿病患者大血管病变的研究分析[J].医师进修杂志,2005,28(11):31-33.
-
2杨玉双,李学宇,麻薇,杨萍.兔动脉粥样硬化模型中NO和PAI-1的表达及阿托伐他汀的干预作用[J].吉林大学学报（医学版）,2007,33(4):671-674. 被引量：8
-
3戴研,高润霖,陈纪林,吴永健,刘海波,秦学文,贾云香,孙继良.冠心病患者血浆纤溶酶原激活物抑制物-1水平的变化[J].临床心血管病杂志,2003,19(11):660-662.
-
4范泉,陶小红,蔡连玲,王永亮,董作佳.血糖异常患者血浆PAI-1活性与糖化血红蛋白水平关系及临床意义[J].齐齐哈尔医学院学报,2011,32(10):1548-1549. 被引量：1
-
5陈世德,陶新智,伍伟锋.心力衰竭患者血浆纤溶酶原激活物抑制物-1与血管紧张素Ⅱ相关性的研究[J].临床心血管病杂志,2003,19(6):336-337. 被引量：13
-
6马雅辉,王立.糖尿病足与胰岛素抵抗及血浆纤溶酶原激活物抑制物-1与肿瘤坏死因子-α的相关性分析[J].中国综合临床,2009,25(8):825-827. 被引量：3
-
7虎子颖,赵建伟.罗格列酮对早期2型糖尿病肾病患者CRP、PAI-1的影响[J].中原医刊,2007,34(20):27-28. 被引量：2
-
8李惠琴,侯为开,陈丽.糖耐量异常及2型糖尿病患者血浆纤溶酶原激活物抑制物-1水平与动脉粥样硬化关系的探讨[J].中国医师进修杂志（内科版）,2006,29(8):26-28. 被引量：5
-
9刘奇英,雷肖红,程医萍.高血压并发高同型半胱氨酸血症患者血浆PAI-1水平分析[J].中西医结合心脑血管病杂志,2014,12(3):297-298.
-
10常敏.慢性肾脏病患者血清同型半胱氨酸与动脉粥样硬化的关系[J].临床医药文献电子杂志,2015,2(25):5201-5202.
